Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

Abstract Self-replicating RNA (srRNA) technology, in comparison to mRNA vaccines, has shown dose-sparing by approximately 10-fold and more durable immune responses. However, no improvements are observed in the adverse events profile. Here, we develop an srRNA vaccine platform with optimized non-codi...

Full description

Saved in:
Bibliographic Details
Main Authors: Christian J. Maine, Shigeki J. Miyake-Stoner, Darina S. Spasova, Gaelle Picarda, Annie C. Chou, Emily D. Brand, Melanie D. Olesiuk, Christine C. Domingo, Hunter J. Little, Thomas T. Goodman, Jacqueline L. Posy, Jasmin Gonzalez, Terrina L. Bayone, Jessica Sparks, Ebony N. Gary, Zhi Xiang, Nicholas J. Tursi, Casey E. Hojecki, Hildegund C. J. Ertl, David B. Weiner, Irafasha C. Casmil, Anna K. Blakney, Brandon Essink, Guillermo Somodevilla, Nathaniel S. Wang, Andrew J. Geall, Zelanna Goldberg, Parinaz Aliahmad
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-55843-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-55843-9

Similar Items